Vette vis tegen astma*
Amerikaanse onderzoekers hebben bij muizen vastgesteld dat een derivaat van omega-3 vetzuren, Resolvine E1 zorgt dat benauwdheid als gevolg van
astma bestreden en voorkomen kan worden. Resolvines worden door enzymen uit omega-3-vetzuren geproduceerd. In het lichaam remt resolvine E1 zowel de migratie van ontstekingscellen naar de plaats van ontsteking, en voorkomt tevens dat andere ontstekingcellen worden geactiveerd.
Potential Role Of Fish-Based Fatty Acids In Resolving, Preventing Asthma
WHAT: In an ongoing effort to determine the anti-inflammatory value of diets rich in some types of fish, scientists studying asthma and allergic reactions have found that a molecule produced by the body from omega-3 fatty acids helps resolve and prevent respiratory distress in laboratory mice. The research, supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, was led by a research team at Brigham and Women's Hospital and Harvard Medical School.
Resolvin E1 (RvE1) is a metabolic product of an omega-3 fatty acid found in cold-water fish such as salmon, mackerel and anchovies. It is made by the body in response to the onset of inflammation. This study identified RvE1 as having a key role in both dampening the development of airway inflammation and promoting its resolution in mice, in part by dampening innate immune signals that trigger inflammation. Other studies have indicated that increased levels of omega-3 fatty acids are associated with lower asthma prevalence in people, but the mechanisms to support that observation are poorly understood. This study provides scientists an opportunity to focus on the role of RvE1 as a potential therapeutic candidate.
ARTICLE: O Haworth et al. Resolvin E1 regulates interleukin-23, interferon-y and lipoxin A4 to promote resolution of allergic airway inflammation. Nature Immunology DOI
10.1038/ni.1627
WHO: Alkis Togias, M.D., Chief of the Asthma and Inflammation Section, NIAID Allergy and Inflammation Branch, is available to comment on this article.
NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and
allergies.
The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.
News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov/.
Source: NIAID Office of Communications
NIH/National Institute of Allergy and Infectious Diseases (Augustus
2008)
